- Home
- CIVB vs IGMS Comparison
CIVB vs IGMS Comparison
Compare CIVB & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIVB
- IGMS
- Stock Information
- Founded
- CIVB 1884
- IGMS 1993
- Country
- CIVB United States
- IGMS United States
- Employees
- CIVB N/A
- IGMS N/A
- Industry
- CIVB Major Banks
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- CIVB Finance
- IGMS Health Care
- Exchange
- CIVB Nasdaq
- IGMS Nasdaq
- Market Cap
- CIVB 315.7M
- IGMS 348.5M
- IPO Year
- CIVB N/A
- IGMS 2019
- Fundamental
- Price
- CIVB $21.30
- IGMS $1.71
- Analyst Decision
- CIVB Buy
- IGMS Hold
- Analyst Count
- CIVB 4
- IGMS 8
- Target Price
- CIVB $21.67
- IGMS $6.14
- AVG Volume (30 Days)
- CIVB 48.2K
- IGMS 783.1K
- Earning Date
- CIVB 01-30-2025
- IGMS 03-06-2025
- Dividend Yield
- CIVB 3.00%
- IGMS N/A
- EPS Growth
- CIVB N/A
- IGMS N/A
- EPS
- CIVB 2.00
- IGMS N/A
- Revenue
- CIVB $146,565,000.00
- IGMS $2,918,000.00
- Revenue This Year
- CIVB N/A
- IGMS $23.57
- Revenue Next Year
- CIVB $6.18
- IGMS $192.36
- P/E Ratio
- CIVB $10.68
- IGMS N/A
- Revenue Growth
- CIVB N/A
- IGMS 57.64
- 52 Week Low
- CIVB $13.60
- IGMS $1.59
- 52 Week High
- CIVB $23.70
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- CIVB 54.73
- IGMS 19.36
- Support Level
- CIVB $20.17
- IGMS $1.59
- Resistance Level
- CIVB $21.29
- IGMS $2.06
- Average True Range (ATR)
- CIVB 0.56
- IGMS 0.41
- MACD
- CIVB 0.12
- IGMS -0.25
- Stochastic Oscillator
- CIVB 95.15
- IGMS 2.18
About CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.